Last reviewed · How we verify

NCT07165470

Pre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease

Not yet recruiting NA Last updated 10 September 2025
What this trial tests

NA trial testing pre-packaged low-residue diet for bowel preparation in Colonoscopy: Bowel Preparation in 500 participants. Not yet recruiting.

Timeline
1 September 2025
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorChanghai Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposediagnostic
Enrollment500
Start date1 September 2025
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Changhai Hospital

Who can join

Adults 18 to 75, any sex, with Colonoscopy: Bowel Preparation or IBD - Inflammatory Bowel Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objectives of this study are as follows: 1.To evaluate the efficacy of Maifu Changqing® Complete Nutritional Formula Powder in bowel preparation for colonoscopy among inflammatory bowel disease (IBD) patients;2.To enhance nutritional status and procedural comfort during bowel preparation in the IBD population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of pre-packaged low-residue diet for bowel preparation

Trials testing the same drug.

Other recruiting trials for Colonoscopy: Bowel Preparation

Currently open trials in the same condition.

Other Changhai Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07165470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing